The investment is part of a five-year effort from Eli Lilly to meet higher demand for diabetes medicine.

Indianapolis-based Eli Lilly, along with two other European pharmaceutical companies, is facing a price-fixing lawsuit regarding its rapidly escalating insulin prices.

Eli Lilly's Solanezumab was a medicine that aimed to reduce symptoms in patients with mild dementia due to Alzheimer's.

The news of layoffs follows last month's announcement concerning the failure of Solanezumab, which Lilly hoped would be the first drug to slow the progression of Alzheimer's Disease.

In a letter, Vermont Sen. Bernie Sanders and Maryland Rep. Elijah Cummings criticize three insulin manufacturers -- including Indianapolis-based Eli Lilly -- for skyrocketing insulin prices.

Lilly's retiring chief, John Lechleiter, led the company to new prosperity during his eight-year tenure.

The $100 million in grant money will help the institute realize its vision to address metabolic disease - like obesity, high blood pressure and diabetes.

The institute plans to focus on heart disease, diabetes and nutrition. It formed in 2013 and already has $50 million on hand from a state grant and private donations.

The philanthropic arm of drugmaker Eli Lilly is increasing its public backing of the United Way.

The emerging treatment is offering new hope for patients and shows promise in shaping the future of cancer treatment.